Print

BioMarin Pharmaceutical Inc. (BMRN) Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU  
6/5/2013 9:28:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU).

Help employers find you! Check out all the jobs and post your resume.

//-->